2,636 Shares in Biogen Inc (BIIB) Acquired by Americafirst Capital Management LLC
Americafirst Capital Management LLC purchased a new stake in Biogen Inc (NASDAQ:BIIB) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,636 shares of the biotechnology company’s stock, valued at approximately $825,000. Biogen makes up about 1.1% of Americafirst Capital Management LLC’s portfolio, making the stock its 10th biggest position.
Several other large investors have also recently modified their holdings of BIIB. Horan Capital Advisors LLC. purchased a new stake in Biogen in the 3rd quarter worth approximately $128,000. Atlantic Trust LLC purchased a new stake in Biogen in the 2nd quarter worth approximately $114,000. Massey Quick Simon & CO. LLC lifted its position in Biogen by 84.8% in the 3rd quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock worth $133,000 after buying an additional 195 shares in the last quarter. Cable Hill Partners LLC lifted its position in Biogen by 224.7% in the 3rd quarter. Cable Hill Partners LLC now owns 487 shares of the biotechnology company’s stock worth $152,000 after buying an additional 337 shares in the last quarter. Finally, Gs Investments Inc. purchased a new stake in Biogen in the 2nd quarter worth approximately $136,000. Institutional investors and hedge funds own 88.30% of the company’s stock.
In other news, Director Alexander J. Denner bought 30,000 shares of the stock in a transaction that occurred on Wednesday, November 29th. The shares were acquired at an average cost of $317.36 per share, for a total transaction of $9,520,800.00. Following the purchase, the director now owns 10,029 shares of the company’s stock, valued at approximately $3,182,803.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.25% of the company’s stock.
Biogen Inc (NASDAQ:BIIB) opened at $330.71 on Thursday. Biogen Inc has a 12 month low of $244.28 and a 12 month high of $348.84. The company has a market cap of $69,940.00, a price-to-earnings ratio of 15.19, a PEG ratio of 2.05 and a beta of 0.73. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.90 and a current ratio of 2.19.
Biogen (NASDAQ:BIIB) last posted its earnings results on Tuesday, October 24th. The biotechnology company reported $6.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.70 by $0.61. Biogen had a net margin of 29.44% and a return on equity of 38.51%. The business had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period last year, the business posted $5.19 EPS. Biogen’s revenue was up 4.1% compared to the same quarter last year. research analysts forecast that Biogen Inc will post 22.03 earnings per share for the current year.
A number of equities research analysts have issued reports on the stock. Royal Bank of Canada reiterated a “hold” rating and issued a $321.00 target price on shares of Biogen in a research report on Tuesday, December 5th. Oppenheimer set a $350.00 target price on shares of Biogen and gave the stock a “buy” rating in a research report on Monday, December 4th. Cowen reiterated a “buy” rating and issued a $338.00 target price on shares of Biogen in a research report on Monday, November 27th. BMO Capital Markets reiterated a “buy” rating and issued a $385.00 target price on shares of Biogen in a research report on Monday, November 27th. Finally, J P Morgan Chase & Co set a $378.00 target price on shares of Biogen and gave the stock a “buy” rating in a research report on Monday, November 27th. Twelve equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. Biogen currently has an average rating of “Buy” and an average price target of $344.60.
TRADEMARK VIOLATION WARNING: “2,636 Shares in Biogen Inc (BIIB) Acquired by Americafirst Capital Management LLC” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/2636-shares-in-biogen-inc-biib-acquired-by-americafirst-capital-management-llc/1762615.html.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with Analyst Ratings Network's FREE daily email newsletter.